Supriya Lifescience Past Earnings Performance
Past criteria checks 4/6
Supriya Lifescience has been growing earnings at an average annual rate of 9.3%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 11.8% per year. Supriya Lifescience's return on equity is 16%, and it has net margins of 21.7%.
Key information
9.3%
Earnings growth rate
7.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.8% |
| Return on equity | 16.0% |
| Net Margin | 21.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Little Excitement Around Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings
May 10
Lacklustre Performance Is Driving Supriya Lifescience Limited's (NSE:SUPRIYA) Low P/E
Feb 09Supriya Lifescience's (NSE:SUPRIYA) Shareholders May Want To Dig Deeper Than Statutory Profit
May 28Market Cool On Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings Pushing Shares 27% Lower
May 07Revenue & Expenses BreakdownBeta
How Supriya Lifescience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5,545 | 1,204 | 832 | 0 |
| 30 Sep 23 | 5,195 | 1,001 | 803 | 0 |
| 30 Jun 23 | 4,916 | 931 | 583 | 0 |
| 31 Mar 23 | 4,609 | 899 | 730 | 0 |
| 31 Dec 22 | 5,069 | 978 | 696 | 0 |
| 30 Sep 22 | 5,188 | 1,280 | 734 | 0 |
| 30 Jun 22 | 5,545 | 1,693 | 534 | 0 |
| 31 Mar 22 | 5,300 | 1,518 | 656 | 0 |
| 31 Dec 21 | 4,754 | 1,543 | 629 | 0 |
| 31 Mar 21 | 3,912 | 1,236 | 501 | 0 |
| 31 Mar 20 | 3,200 | 734 | 345 | 0 |
| 31 Mar 19 | 2,818 | 394 | 261 | 0 |
| 31 Mar 18 | 2,168 | 87 | 230 | 0 |
Quality Earnings: SUPRIYA has high quality earnings.
Growing Profit Margin: SUPRIYA's current net profit margins (21.7%) are higher than last year (19.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SUPRIYA's earnings have grown by 9.3% per year over the past 5 years.
Accelerating Growth: SUPRIYA's earnings growth over the past year (23.1%) exceeds its 5-year average (9.3% per year).
Earnings vs Industry: SUPRIYA earnings growth over the past year (23.1%) did not outperform the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: SUPRIYA's Return on Equity (16%) is considered low.